MRNA vs NVAX
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 02, 2026
MRNA
51.3
AI Score
VS
NVAX Wins
NVAX
56.4
AI Score
Investment Advisor Scores
NVAX
56score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | MRNA | NVAX | Winner |
|---|---|---|---|
| Revenue | 139.51M | 534.00M | MRNA |
| Net Income | -9.49M | -2.13B | NVAX |
| Net Margin | -6.8% | -397.9% | NVAX |
| Operating Income | -15.43M | -2.20B | NVAX |
| ROE | 6.6% | -31.4% | NVAX |
| ROA | -0.9% | -19.4% | NVAX |
| Total Assets | 1.04B | 10.96B | MRNA |
| Cash | 228.36M | 1.72B | MRNA |
| Debt/Equity | -2.01 | 0.09 | NVAX |
| Current Ratio | 2.48 | 2.29 | NVAX |
Relative Price Performance (Last 90 Days)
MRNA 1M: -24.4%
· 3M: +19.3%
NVAX 1M: -22.6%
· 3M: -7.6%
Current Technical Phase
MRNA
NeutralHold
Mixed signals - no dominant trend phase, RSI 41
NVAX
MarkdownSell / avoid
Price below a falling SMA50 (slope -2.0%), weak momentum, RSI 30
Fundamentals Snapshot
| Metric | MRNA | NVAX |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -11.5 | -28.8 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 2.6% | -0.8% |
| Gross Margin | -0.7% | 0.3% |
| Operating Margin | -1.3% | -0.1% |
| EPS | -8.14 | -0.55 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, NVAX is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.